Anixa Biosciences Inc
ANIX · Pharmaceutical Preparations · 34.0M shares · +4%/yr ↑ dilution · EDGAR filings ↗
Net buyback after stock comp: -$4M (gross $6K, SBC $4M)
Reference price $2.64 · est. market cap ~$90M — last insider purchase, 2026-06-16 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D44Clinical-stage oncology biotech — pre-revenue and loss-making, but funded.
Strengths
- Strong liquidity — current ratio 8.1 (73rd)
Risks
- Pre-revenue, deep losses — ROE -72%, ROA -68%
- Pre-revenue/clinical-stage — history of losses & need for additional capital per risk factors
- Binary pipeline (cancer vaccine/CAR-T) risk — per 10-K
Notable findings
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Insider buyingInsider buying — 3 open-market buy(s) by 3 insider(s) (cluster of 3 insiders, last 6mo) Form 4 ↗
- Notable holderHeld by 3 notable fund(s): STATE STREET CORP, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Return on equity
-72.1%
Return on assets
-68.0%
Current ratio
8.1×
Tangible book value
$15M
Cash & investments
$15M
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-16 | Titterton Lewis H jr | Buy | 2.8K | $2.64 |
| 2026-06-12 | KUMAR AMIT | Buy | 21K | $2.50 |
| 2026-01-28 | Baskies Arnold M | Buy | 10K | $3.04 |
| 2025-12-15 | Titterton Lewis H jr | Option exercise | 16K | $2.92 |
| 2025-10-30 | KUMAR AMIT | Option exercise | 200K | $2.92 |
| 2025-10-30 | KUMAR AMIT | Tax withheld | 169K | $4.06 |
| 2025-07-31 | Titterton Lewis H jr | Buy | 10K | $3.08 |
| 2025-07-30 | KUMAR AMIT | Buy | 5.0K | $3.16 |
| 2025-07-18 | Baskies Arnold M | Buy | 5.0K | $3.39 |
| 2025-07-11 | KUMAR AMIT | Buy | 5.0K | $3.15 |
| 2025-07-11 | Titterton Lewis H jr | Buy | 10K | $3.14 |
| 2025-06-04 | KUMAR AMIT | Buy | 10K | $2.85 |
| 2025-01-28 | Baskies Arnold M | Buy | 5.0K | $2.82 |
| 2025-01-24 | Titterton Lewis H jr | Buy | 1.0K | $3.00 |
| 2025-01-23 | Titterton Lewis H jr | Buy | 2.0K | $2.91 |
| 2025-01-22 | Titterton Lewis H jr | Buy | 2.0K | $3.01 |
| 2025-01-21 | Titterton Lewis H jr | Buy | 6.0K | $2.59 |
| 2025-01-17 | Titterton Lewis H jr | Buy | 10K | $2.57 |
| 2025-01-15 | KUMAR AMIT | Buy | 43K | $2.23 |
| 2025-01-15 | Catelani Michael | Buy | 9.3K | $2.15 |
All non-derivative Form 4 activity (SEC), newest first.
Supply chain
Customers (0)
Suppliers (3)
- The Cleveland Clinic Foundation
- H. Lee Moffitt Cancer Center and Research Institute, Inc.
- The Wistar Institute
Named in the 10-K; linked when we track them.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-03-11 | Shareholder voteReg FDExhibits | filing ↗ |
| 2026-02-09 | Reg FDExhibits | filing ↗ |
| 2025-12-12 | Reg FDExhibits | filing ↗ |
| 2025-03-21 | Shareholder voteReg FDExhibits | filing ↗ |
| 2024-11-08 | Reg FDExhibits | filing ↗ |
| 2024-05-08 | Material agreementReg FDExhibits | filing ↗ |
| 2024-03-22 | Shareholder voteReg FDExhibits | filing ↗ |
| 2023-12-07 | Reg FDExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 10-Q | 2026-06-10 | 2026-04-30 | 0001493152-26-028105 ↗ |
| 8-K | 2026-03-11 | 2026-03-10 | 0001493152-26-009699 ↗ |
| 10-Q | 2026-03-09 | 2026-01-31 | 0001493152-26-009370 ↗ |
| 8-K | 2026-02-09 | 2026-02-09 | 0001493152-26-005702 ↗ |
| 10-K | 2026-01-12 | 2025-10-31 | 0001493152-26-001845 ↗ |
| 8-K | 2025-12-12 | 2025-12-11 | 0001493152-25-027321 ↗ |
| 10-Q | 2025-09-10 | 2025-07-31 | 0001493152-25-013000 ↗ |
| 10-Q | 2025-05-28 | 2025-04-30 | 0001641172-25-012701 ↗ |
| 8-K | 2025-03-21 | 2025-03-20 | 0001493152-25-011151 ↗ |
| 10-Q | 2025-03-11 | 2025-01-31 | 0001493152-25-009854 ↗ |
| 10-K | 2025-01-10 | 2024-10-31 | 0001493152-25-001787 ↗ |
| 8-K | 2024-11-08 | 2024-11-08 | 0001493152-24-044224 ↗ |